Zolinza (vorinostat) can prevent GVHD
Hi All,
The histone deacetylase inhibitor Zolinza (vorinostat) can prevent GVHD in many patients: https://ash.confex.com/ash/2012/webp...aper47682.html Kind regards Birgitta-A |
They call it a "proof of concept first-in-human phase I/II clinical trial" but oral vorinostat certainly made a difference in the trial, with severe acute GVHD reduced from 19% to 4%, less severe aGVHD reduced from 42% to 22%, and mortality reduced from 19% to 13% when comparing the study control group to the vorinostat group.
Despite the small scope of the trial, this is very promising. I wonder if vorinostat would make a difference after the fact for patients with GVHD or if its only target is preventing GVHD. |
All times are GMT -4. The time now is 01:11 PM. |
Powered by vBulletin® Version 3.6.7
Copyright ©2000 - 2025, Jelsoft Enterprises Ltd.
Forum sites may contain non-authoritative and unverified information.
Medical decisions should be made in consultation with qualified medical professionals.
Site contents exclusive of member posts Copyright © 2006-2020 Marrowforums.org